Gonzalez-Cantero, AlvaroTeklu, MeronSorokin, Alexander VPrussick, RonaldGonzález-Cantero, JorgeMartin-Rodriguez, Jose LuisPatel, NidhiParel, Philip MManyak, Grigory ATeague, Heather LRodante, Justin AKeel, AndrewPérez-Hortet, CristinaSanchéz-Moya, Ana IJiménez, NataliaBallester, AsunciónSolis, JorgeFernandez-Friera, LeticiaBarderas, María GGonzalez-Calvin, Jorge LJaen, PedroPlayford, Martin PDey, Amit KGelfand, Joel MMehta, Nehal N2023-05-032023-05-032021-07-19http://hdl.handle.net/10668/22319Psoriasis is associated with a higher risk of liver diseases. We investigated the impact of hepatic steatosis (European cohort) and hepatic inflammation (United States cohort) on subclinical atherosclerosis. In the European cohort (n = 76 psoriasis participants and 76 controls), nonalcoholic fatty liver disease, assessed by the sonographic hepatorenal index, was more prevalent in psoriasis than in controls (61% vs. 45%; P = 0.04). Participants with psoriasis with nonalcoholic fatty liver disease had a higher prevalence of subclinical atherosclerosis (ultrasonographic presence of plaque in femoral or carotid arteries) than participants with psoriasis without nonalcoholic fatty liver disease (61% vs. 23%; P = 0.006) and controls with nonalcoholic fatty liver disease (61% vs. 32%; PenAdultAtherosclerosisCarotid ArteriesCohort StudiesComputed Tomography AngiographyEuropeFatty LiverFemaleHumansMaleMiddle AgedNon-alcoholic Fatty Liver DiseasePositron-Emission TomographyPrevalencePsoriasisRisk FactorsUnited Statesresearch article34293354open access10.1016/j.jid.2021.05.0341523-1747https://doi.org/10.1016/j.jid.2021.05.034